Tesamorelin Effects on Liver Fat and Histology in HIV

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2015

Primary Completion Date

January 16, 2019

Study Completion Date

July 24, 2019

Conditions

Human Immunodeficiency Virus (HIV)Nonalcoholic Fatty Liver Disease (NAFLD)Nonalcoholic Steatohepatitis (NASH)

Interventions

DRUG

tesamorelin

DRUG

Placebo

inactive substance that looks like tesamorelin

Trial Locations (2)

National Institutes of Health, Bethesda

Massachusetts General Hospital, Boston

All Listed Sponsors

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Massachusetts General Hospital

OTHER

NCT02196831 - Tesamorelin Effects on Liver Fat and Histology in HIV | Biotech Hunter | Biotech Hunter